SCHEMBL6080460

SCHEMBL6080460

N#Cc1cc(CCc2ccccc2)cc2c(O)cc(C(=O)O)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
P2RX3 P56373 1/20 0.37
EGLN2 Q96KS0 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 1/20 0.37
CSNK2A1 P68400 1/20 0.37
SLC22A12 Q96S37 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ASPH Q12797 1/20 0.35
RIOX2 Q8IUF8 1/20 0.35
KDM8 Q8N371 1/20 0.35
HTT P42858 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
HCAR2 Q8TDS4 1/20 0.35
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080503 0.88 ALDH1A1 (0.44) SMN1; SMN2POLBRAB9AEGLN2EGLN1
SCHEMBL6079837 0.84 P2RX3 (0.42) P2RX3EGLN1CSNK2A2CSNK2BCSNK2A1
SCHEMBL6080495 0.84 XDH (0.35) XDHPOLBRAB9AKDM4EHCAR2
SCHEMBL6080290 0.81 MCL1 (0.40) XDHKDM4EALDH1A1
SCHEMBL6080777 0.81 P2RX3 (0.39) P2RX3EGLN1CSNK2A2CSNK2BCSNK2A1
SCHEMBL6593629 0.78 ALOX5 (0.49) POLBP2RX3KDM4E
SCHEMBL6080506 0.78 P2RX3 (0.43) SMN1; SMN2POLBRAB9AP2RX3EGLN2
SCHEMBL6080470 0.78 KDM4E (0.43) XDHRAB9AKDM4E
SCHEMBL6080939 0.77 GPR35 (0.34) XDHSMN1; SMN2RAB9AKDM4EALDH1A1
SCHEMBL6080733 0.76 KDM4E (0.43) RAB9AP2RX3CSNK2A2CSNK2BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed
EP-1451159-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2004-09-01 EP disclosed
WO-2003010146-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL XDH 128/4885SMN1; SMN2 2666/4885POLB 2489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.